Polivy Injection Uses
Polivy (Polatuzumab Vedotin-piiq) is a CD79b-directed antibody drug conjugate used in combination with medications bendamustine and a rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, following at least two prior therapies.
Dosage: The recommended dose of Polivy is 1.8 mg/kg as an intravenous infusion over 90 minutes every 21 days for 6 cycles along with bendamustine and a rituximab. Subsequent infusions may be administered over 30 minutes in case the previous infusion is tolerated. Premedicate with an antihistamine and antipyretic before polatuzumab vedotin. If a planned polivy dose is missed, administer as soon as possible. Adjust the schedule of administration to maintain a 21-day interval between doses.
Side Effects: The most commonly reported polatuzumab vedotin side effects include:
- Peripheral neuropathy
- Decreased appetite
Warnings and Precautions:
- Monitor patients with polatuzumab vedotin for infusion-related reactions during the infusion and for a minimum of 90 minutes after the initial dose.
- Administer an antipyretic and antihistamine prior to the use of polivy, and monitor patients closely throughout the infusion.
- Monitor patients with polivy uses for signs of peripheral neuropathy such as hyperesthesia, hypoesthesia, gait disturbance, paresthesia, dysesthesia, neuropathic pain, burning sensation, or weakness.
- Patients with polatuzumab vedotin 140 mg injection should be monitored for complete blood counts throughout treatment.
- Females of reproductive potential are advised of the potential risk to a fetus and should contact their healthcare professional if they become pregnant, or if pregnancy is suspected, during therapy with polatuzumab vedotin.
- Women with polatuzumab vedotin fda label medication are advised to avoid breastfeeding while on polatuzumab vedotin and for at least two months following the last dose.